Amber Meskens

Radionuclide therapy is a treatment already used in many cancer patients. By administering a radioactive product, toxic effects can occur at certain sites in the body. 
The aim of my preclinical research is to examine whether a diagnostic radioisotope, normally used for tumor imaging, can predict the distribution of a therapeutic radioisotope in the body that is typically administered as a treatment. The healthy organs that could be potentially damaged after the treatment can then be mapped without the need to already administer a therapeutic radioisotope. In this way, a personalized safe treatment can be developed for each patient.
The secondary goal of my project is to evaluate and compare the efficacy and toxicity of radiopharmaceuticals emitting different types of radiation in the treatment of oral squamous cell carcinoma in murine models. This may help in the future to improve the quality of life for people diagnosed with oral squamous cell carcinoma and possibly also for other epithelial tumors.
 

• 2023: Master of Science in Biomedical Sciences at Ghent University
   

• Lab Address: Campus Heymans, Ottergemsesteenweg 460, 9000 Gent (FW02)
• Infinity Lab 
• LinkedIn 
• Amber Meskens is interested to receive invitations for presentations or talks